A significant trend reveals that about 25.8% of buprenorphine prescriptions for opioid use disorder were never filled or dispensed between 2020 and 2024. Data from a recent study in JAMA Network Open shows this rate climbed from 19% in 2020 to 37% by 2024. This increase highlights a missed opportunity for medical intervention during a critical period of care.
Patients who abandoned their prescriptions were more likely to be younger, Hispanic, and covered by commercial insurance rather than other plans. High pharmacy deductibles also played a clear role, as those who did not fill their orders faced higher out-of-pocket costs on average. These financial hurdles appear to be a primary barrier to consistent treatment.
Clinicians now face the task of navigating these logistical gaps. While buprenorphine effectively reduces mortality risk, the current pharmacy and patient-level barriers undermine these clinical efforts. Experts suggest that improving prescription fill rates requires reducing insurance coverage restrictions and ensuring pharmacies reliably stock the medication.
Support systems also play an important role in patient outcomes. Connecting individuals to navigators who can help locate pharmacies or identify low-cost programs may prevent these lapses. Addressing these barriers is necessary to ensure that individuals seeking help for opioid use disorder can access the treatment they need.